Lumos Pharma to Participate in World Orphan Drug Congress USA
22 Maggio 2023 - 3:00PM
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company
advancing an oral therapeutic candidate for idiopathic Pediatric
Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials,
announced today that management will participate in panel
discussions at the World Orphan Drug Congress USA 2023, held in
Washington, D.C., May 23-25, 2023. John McKew, PhD, the Company’s
President and Chief Scientific Officer, and Aaron Schuchart, its
Chief Business Officer, will be participating in panel discussions
as follows:
- May 24th, 4:20-5:00 PM ET -
Patient Focused Drug Development - Best Practices on
Patient Group and Drug Developer Interaction With FDA,
John McKew, PhD, President & CSO
- May 25th, 11:10-11:50 AM ET
–Partnering in The Rare Disease Space – Industry
Perspectives, Aaron Schuchart, CBO
About the World Orphan Drug
Congress
The World Orphan Drug Congress brings together
leading pharmaceutical and biotech companies, government and
regulatory authorities, patient advocacy groups, payers, investors
and solution providers. The conference is a place to meet and
brainstorm ways to advance orphan drug development and improve
access to life-saving therapies.
To register for the Congress, click here.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage
biopharmaceutical company focused on the development and
commercialization of therapeutics for rare diseases. Lumos Pharma
was founded and is led by a management team with longstanding
experience in rare disease drug development. Lumos Pharma’s lead
therapeutic candidate is LUM-201, an oral growth hormone
stimulating small molecule, currently being evaluated in several
Phase 2 clinical trials for the treatment of idiopathic Pediatric
Growth Hormone Deficiency (iPGHD): the dose-finding OraGrowtH210
Trial; the PK/PD mechanistic OraGrowtH212 Trial; and a switch
trial, the OraGrowtH213 Trial. If approved by the FDA, LUM-201
would provide an orally administered alternative to recombinant
growth hormone injections that PGHD subjects otherwise endure for
many years of treatment. LUM-201 has received Orphan Drug
Designation in both the US and EU. For more information, please
visit https://lumos-pharma.com/.
Investor & Media
Contact:
Lisa MillerLumos Pharma Investor
Relations512-792-5454ir@lumos-pharma.com
Grafico Azioni Lumos Pharma (NASDAQ:LUMO)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Lumos Pharma (NASDAQ:LUMO)
Storico
Da Giu 2023 a Giu 2024